GRACE :: Lung Cancer

ASCO vs. NCCN: Very Different Views on Molecular Testing in Advanced NSCLC

download as a pdf file Download PDF of this page

A couple of weeks ago, the American Society of Clinical Oncology (ASCO) released a set of revised guidelines for stage IV NSCLC. While grounded in good evidence, they are striking for the contrast they offer with the recommended strategy from the National Comprehensive Cancer Network (NCCN) guidelines for this population. Most notably, the difference is related to molecular testing and subsequent individualized treatment based on this. As many of you who follow the discussions here have observed, the question of who to test and what to test for is currently among the most timely, evolving, and still somewhat controversial questions in the practice of lung cancer today. This is especially true in the setting of the approval of the ALK inhibitor XALKORI (crizotinib) by the FDA just a few weeks ago, since this agent is only going to be made commercially available to the 4-5% of patients with NSCLC who test positive for an ALK rearrangement at the one designated central lab approved along by the FDA along with the drug. So here, the approval of the drug is actually predicated on molecular testing for patients who would hope to receive this agent.

The NCCN guidelines, released earlier this year, recommend testing for the EGFR mutation all patients with advanced/metastatic non-squamous NSCLC, with the subsequent recommendation of the EGFR tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) as first line treatment for patients with a demonstrated EGFR mutation. While ALK testing and crizotinib are not mentioned, this is not surprising, since neither was commercially available when the last version of their guidelines was released. Frankly, I found these guidelines to be just a little “forward-thinking” in calling for anyone with non-squamous NSCLC to be tested, since people with a very significant smoking history would have a quite low, even if non-zero, chance of having an EGFR mutation. Moreover, while many studies have now shown that people with an EGFR mutation have a consistently longer progression-free survival and response rate with first line EGFR TKI compared with first line chemo, there isn’t clear evidence that survival is worse if people with an EGFR mutation receive an EGFR TKI after first line (in other words, A + B = B + A). Since EGFR inhibitors are readily available regardless of smoking status or NSCLC subtype (in the US, at least), it’s not quite clear that it’s critical to test everyone immediately after diagnosis. They key may just be that everyone who could possibly have an EGFR mutation gets their opportunity with an EGFR TKI, sooner or later. That said, the ALK story adds a level of complexity now, since XALKORI isn’t an option if you aren’t tested. But that’s not yet addressed in any formal guidelines.

ASCO guidelines offer a very different interpretation. Specifically, they note that collecting tumor tissue can be a practical challenge and that molecular testing is currently considered as investigational rahter than the standard of care. Moreover, even patients who are found to have an activating EGFR mutation, an EGFR TKI is considered an acceptable alternative to standard chemotherapy but not a definite superior choice, since at this point there hasn’t been a significant survival benefit to first line EGFR TKI demonstrated in such patients. (And again, not surprisingly, no mention of ALK testing or XALKORI.)

My interpretation of these two sets of guidelines, with their very different, rather polarized views, is that most oncologists will (and probably should) fall within the spectrum between these extremes. Personally I believe that the NCCN decree for testing in all non-squamous patients, without evidence that an EGFR mutation is present in more than a vanishingly small proportion of longtime smokers with large cell NSCLC, for instance, and without evidence that testing delivers a survival benefit, is rather heavy handed. I see the guidelines as a reflection of the bias by many academic oncologists who don’t have much of a concept of the practical limitations of obtaining tissue in clinics outside of academic centers, or the frustrations and delays of ordering mutation testing in labs in another state rather than in the same building where you work.

On the other hand, I would definitely say that the data supporting treating patients with an EGFR mutation with an EGFR TKI relatively early, including in the first line setting most of the time, supports the value of testing patients with a reasonable probability of having an EGFR mutation (many patients with an adenocarcinoma, many patients who are ex-smokers or never-smokers, regardless of tumor histology), and of favoring an EGFR TKI over chemo in EGFR mutation patients. Even if the data don’t support a declaration that EGFR mutation or other molecular testing is a mandate, calling all such testing “investigational” is, in my mind, an oversimplification in the other direction. As with the NCCN guidelines, the ASCO guidelines are a reflection of the group that developed them: ASCO represents the broad range of rank and file oncologists, who see more patients in the community setting who may have little tissue available from an initial biopsy and who may be more resistant to another invasive procedure, especially if molecular testing entails a delay of several weeks before results are available and treatment can be initiated.

The ground has been shifting under our feet, as new information comes in, pretty much in real time, with every new cancer meeting and even with new issues of our monthly journals. This debate will continue, a product of differences in how much evidence different oncologists (and patients) need to change their practice.

Today, molecular testing for a group of patients with a high pre-test probability can provide the only way to receive crizotinib for appropriate patients, it can direct us to give EGFR TKI therapy as early as possible to patients with an EGFR mutation (who might develop a complication along the way that precludes them from getting it later), and I do honestly believe it will come to revolutionize how we see, categorize, and treat lung cancer (and other cancers) over the next decade. It’s our way into the future, but I don’t think the data quite support mandating it for nearly every patient in the present.

6 Responses to ASCO vs. NCCN: Very Different Views on Molecular Testing in Advanced NSCLC

  • macleanb says:

    As usual Dr West – a balanced, thoughtful interpretation. Any news on what George Simon is up to?

  • graceabchen says:

    Dr. West, thanks for providing the information. Having benefitted from EGFR test and TKI, I do not feel that having molecular testing done as early as possible for all nsclc adenocarcinoma is a bad idea. Doing so, patients who deserve first-line targeted therapies won’t miss that opportunity. I think that your concerns become less compelling when comparing with the overall possible benefits that a positive mutation can have. However, my understanding may not be correct. Thus, I would appreciate your response to the following questions : 1. What is the probability that people with a very significant smoking history would have a positive EGFR or AKL mutation for Caucasians ?, and for Asians? 2. How much is known about the long-term survival benefit for the first-line EGFR TKI stage-4 lc patients? How is it compared to other therapies? 3. I doubt many patients with positive EGFR would start with chemo therapy. Actually, I think that it is probably not a bad idea for a stage-4 nsclc adenocarcinoma patient to start TKI right the way before knowing the mutation result, because it does not take long to know the response. One can always switch to other therapies if it does work. Also, although rare, some patients with negative EGFR do respond to TKI. Thank you for your patience. AB

  • Dr West says:

    The percentages of people with an EGFR mutation among current or long-time smokers is in the very low single digits for Caucasians, probably drifting up to the higher single digits for Asian smokers.

    There is no real evidence that people who have an EGFR mutation and get an EGFR inhibitor as maintenance therapy or second or third line therapy have a worse survival than if they get it early. Obviously, it’s important for them to get an EGFR tyrosine kinase inhibitor at some point, but it’s not proven that the timing matters.

    Actually, that’s only true if you’re talking about having an EGFR mutation. If you don’t know if someone has an EGFR mutation, there is convincing evidence that it’s detrimental to give an EGFR inhibitor before first line chemo. This is especially well illustrated in the TORCH trial, described in the link below:

    -Dr. West

  • hopey5000 says:

    Interesting and educational comment.

    1. Sorry but adminsitrative problems of the physician are going to be of little concern here.

    2. However, the risks of surgery or medical procedures are a legitimate concern. What is involved with obtaining tissue sufficient for EGFR or ALK measurement.

    3. Once we get the tissue, does it make sense to test for Cox-2 or KRAS. While it does not appear either are likely to regularly provide the homerun that EGFR identification does, they may impact treatment. Remember for the patient, the question is not whether Cox-2 or KRAS treatment is reliable, but whether it offers alternatives better than existing treatments.

    4. Do note that even if EGFR testing is unlikely to provide EGFR positive patients among heavier smokers, it may reveal patients with the cellular combination that in one study predicted response to Tarceva outside the EGFR positive population.

  • Dr West says:

    The tissue is the same as getting a biopsy for diagnostic reasons. It depends on what is accessible, and the more tissue, the better. Generally, a core biopsy is sufficient.

    Right now, there is no evidence that KRAS mutation testing or COX-2 testing has any utility in guiding clinical practice. This isn’t to say that these tests never well prove to have value, but if they cost money, require tissue, and have no clear value in improving outcomes, it’s hard to argue forcefully for them.

    -Dr. West

  • Dr West says:

    He’s moved to Medical University of South Carolina and is still working on similar research. His phase III “MADE-IT” trial of customized therapy based on potential molecular markers predictive of chemotherapy benefit is ongoing or may be completed now, but we haven’t heard any results yet. Perhaps we’ll see him present those results in the next year.

    He’s a friend and has done a podcast with me a few years ago. I’d love to get him to participate on GRACE regularly, as a guest faculty member, and though he’s a big fan of GRACE, he’s been so busy he can’t commit to that.

    -Dr. West

  • kapleasants says:

    Dr. West, Where is the ‘one designated central lab’ for ALK testing referred to above? My 24 month PFS with Alimta (as maintenance) has come to an end sadly, and I’m thinking my best bet may be to try Crizontinib. I do not have the EGFR mutation, and do have BAC. I haven’t spoken with my doctor yet about this but would like to know your views on the efficacy (or not)of Xalkori after Alimta. Many thanks, Kathy P.

  • Dr West says:

    The status has been changing, and there are now several labs doing testing that would qualify a patient for XALKORI if ALK testing is positive. Your local pathology lab may have a specific partner, but you could also call 1-877-744-5675 for these kind of practical questions about pursuing ALK testing and potentially XALKORI.

    The evidence for XALKORI after Alimta looks quite positive. In the absence of new information, I would definitely be inclined to offer XALKORI as a (and almost certainly THE) leading treatment option for an ALK-positive patient with advanced NSCLC, whether they have received Alimta previously or not.

    Good luck.

    -Dr. West

Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content


download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos




2015 Acquired Resistance in Lung Cancer Patient Forum Videos

download as a pdf file Download PDF of this page

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
   (Free Newsletter)

Other Resources

download as a pdf file Download PDF of this page

Biomedical Learning Institute